share_log

B of A Securities Maintains Neutral on Axsome Therapeutics, Lowers Price Target to $95

B of A Securities Maintains Neutral on Axsome Therapeutics, Lowers Price Target to $95

美國銀行證券對axsome therapeutics保持中立,將目標股價下調至95美元
Benzinga ·  07/18 12:50

B of A Securities analyst Jason Gerberry maintains Axsome Therapeutics (NASDAQ:AXSM) with a Neutral and lowers the price target from $97 to $95.

BofA證券分析師Jason Gerberry維持Axsome Therapeutics(納斯達克:axsome therapeutics)的中立評級,並將價格目標從97美元下調至95美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論